Session VI: Colorectal Cancer I



Late-Breaking Abstract-5: ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab In previously untreated BRAF V600E–mutant metastatic colorectal cancer


Late-Breaking Abstract-7: Encorafenib (ENCO) plus Cetuximab (CETUX) With or Without Binimetinib (BINI) for BRAFV600E Metastatic Colorectal Cancer (mCRC): Relationship Between Carcinoembryonic Antigen (CEA), and Clinical Outcomes from BEACON CRC


Merck Satellite Symposium:

Meet the Experts: Role of Anti-EGFRs beyond the First Line (1L) - Later Line Treatment Opportunities

Webcast from Wednesday, July 1 (Needs registration at WCGIC)


Short Oral-16: The tumour-stroma ratio as additional parameter to the TNM classification; the UNITED Study


Short Oral-17: Association between tumor budding grade to T stage as prognostic value for recurrence with high-risk stage II colon cancer; a retrospective study


Short Oral-18: Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): main results of the AXOAXI-trial


Short Oral-19: S-1 is a cost-effective alternative to capecitabine in metastatic colorectal cancer


Short Oral-20: Consensus Molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): prognostic and predictive impact in the TRIBE2 study


Short Oral-21: Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)


P-18 REMARRY and PURSUIT trials: Liquid biopsy-guided re-challenge of anti-EGFR monoclonal antibody for patients with RAS/BRAF V600E wild-type metastatic colorectal cancer (Abstract on page S95) ongoing study


Short Oral-22: Atypical non-V600E BRAF (aBRAF) mutations as a prognostic and predictive factor in real-life metastatic colorectal cancer patients from the Nordic countries


Short Oral-23: Prognostic impact of microsatellite instability/mismatch repair deficiency on patients with stage III colon cancer and stage IV colorectal cancers (CRC): analysis of 42,984 Patients in the National Cancer Database (NCDB)


Oral-16: Relative impact of T4 and N2 on the efficacy of 3 versus 6 months of adjuvant CAPOX for high-risk stage II and stage III colon cancer: ACHIEVE and ACHIEVE-2 trials


Oral-17: A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study


Oral-18: Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study


Oral-19: Feasibility of switching patients to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for gastrointestinal cancer



Posters with trifluridine/tipiracil

PD-7 Updated survival analysis of the Danish randomized study comparing trifluridine/tipiracil with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer (abstract on page S214)

The authors conclude that updated survival analyses confirm that FTD/TPI in combination with bevacizumab prolongs PFS and OS and is a new valuable option in patients with chemo-refractory mCRC. Results on markers for no benefit and time to deterioration of performance status will be presented.


P-33 Regorafenib and trifluridine/tipiracil efficacy and safety in chemorefractory metastatic colorectal cancer patients: A single Bulgarian centre retrospective study  (abstract on page S100)

The authors conclude that their real-life single-center results show that regorafenib and trifluridine/tipiracil have similar efficacy and safety among the Bulgarian population compared with previously acquired global data.


P-57 Effectiveness and safety of trifluridine/tipiracil in patients with metastatic colorectal cancer in clinical practice in Poland (abstract on page S108)

The authors conclude that their data show that treatment with trifluridine/tipiracil in daily clinical practice is feasible and safe. Forty-eight patients (39%) achieved clinical benefit with trifluridine/tipiracil. Patient characteristics such as left side primary tumor location, WT KRAS status, WT BRAF status, more than 3 lines of previous treatment, ECOG PS 0, and Platelet-to-Lymphocyte Ratio.


P-147 Efficacy and safety data of trifluridine/tipiracil treatment in advanced colorectal cancer based on the experience of Juan Ramón Jiménez Hospital in Huelva (Abstract on page 137)

The authors conclude that comparing their data with those of the RECOURSE study, they can say that the SG and PFS of their patients were significantly lower. This may be due to the fact that they included patients with ECOG 2, rapid progressors, as well as a higher percentage of patients who required hospital admission due to toxicity. The adverse events of their patients were similar to those described in the RECOURSE study, except for asthenia and febrile neutropenia, which were significantly higher in their study.


P-190 A retrospective study of regorafenib versus trifluridine/tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: Multi-institution real-life clinical data (Abstract on page 152)

The authors conclude that no significant difference between regorafenib and TAS-102 sequence treatments was observed in patients with mCRC. Further analyses are ongoing to potentially identify a biomarker or a clinical sub-group to distinguish the two drugs.


P-195 Treatment outcomes of trifluridine/tipiracil therapy in refractory metastatic colorectal cancer: A single-centre observational study (Abstract on page 154)

The authors aimed to investigate the outcomes and safety of TAS-102 treatment in a real-world setting. Their results, being comparable with previously reported studies, further demonstrate the clinical benefit of TAS-102 for refractory mCRC patients with manageable toxicities. Furthermore, the benefit was derived regardless of tumor characteristics or previous treatment received.


P-339 Real-world data (RWD) of the use of trifluridine/tipiracil hydrochloride (TFT) in patients with metastatic colorectal cancer: The Greater Manchester experience (Abstract on page 200)

The authors conclude that their RWD on TFT was associated with a better OS than expected. This RWD study was able to validate GPC, GPC with no liver metastases and grade